Pemetrexed in advanced non-small cell lung cancer

被引：20

作者：

Gridelli, Cesare ^{[1
]}

Maione, Paolo ^{[1
]}

Rossi, Antonio ^{[1
]}

Bareschino, Maria Anna ^{[1
]}

Schettino, Clorinda ^{[1
]}

Sacco, Paola Claudia ^{[1
]}

Zeppa, Rosario ^{[1
]}

机构：

[1] SG Moscati Hosp, Div Med Oncol, I-83100 Avellino, Italy

来源：

EXPERT OPINION ON DRUG SAFETY | 2011年 / 10卷 / 02期

关键词：

chemotherapy; NSCLC; pemetrexed; safety; PHASE-III TRIAL; CISPLATIN PLUS GEMCITABINE; 1ST-LINE CHEMOTHERAPY; CARBOPLATIN; BEVACIZUMAB; PACLITAXEL; ANTIFOLATE; GEFITINIB; DOCETAXEL; LY231514;

D O I：

10.1517/14740338.2011.553281

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: For patients with advanced NSCLC, treatment outcomes are still disappointing and the search for new active and safe drugs is warranted. The chemotherapeutic agent pemetrexed has produced, in the last years, an innovation of therapeutic algorithms of this disease, and this review is aimed at describing the role of pemetrexed in the treatment of NSCLC. Areas covered: In the present review, we discuss the mechanism of action of pemetrexed, its safety profile and the main clinical data on pemetrexed in NSCLC treatment. The reader will gain information on pemetrexed efficacy in the first-line, second-line and maintenance treatment of advanced NSCLC. Moreover, the histotype-based approach to NSCLC treatment, which is important for the selection of patients to be treated with pemetrexed, is clarified. Expert opinion: The recent introduction of pemetrexed in the first-line and maintenance treatment of advanced non-squamous NSCLC represents, in our opinion, a significant step forward in the treatment of this disease in the last 3 years. Furthermore, cisplatin plus pemetrexed has a more favorable safety profile as compared with those of pre-existing cisplatin-based regimens.

引用

页码：311 / 317

页数：7

共 27 条

[11] Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [J].

Mitsudomi, Tetsuya ;

Morita, Satoshi ;

Yatabe, Yasushi ;

Negoro, Shunichi ;

Okamoto, Isamu ;

Tsurutani, Junji ;

Seto, Takashi ;

Satouchi, Miyako ;

Tada, Hirohito ;

Hirashima, Tomonori ;

Asami, Kazuhiro ;

Katakami, Nobuyuki ;

Takada, Minoru ;

Yoshioka, Hiroshige ;

Shibata, Kazuhiko ;

Kudoh, Shinzoh ;

Shimizu, Eiji ;

Saito, Hiroshi ;

Toyooka, Shinichi ;

Nakagawa, Kazuhiko ;

Fukuoka, Masahiro .

LANCET ONCOLOGY, 2010, 11 (02) :121-128

[12] Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J].

Mok, Tony S. ;

Wu, Yi-Long ;

Thongprasert, Sumitra ;

Yang, Chih-Hsin ;

Chu, Da-Tong ;

Saijo, Nagahiro ;

Sunpaweravong, Patrapim ;

Han, Baohui ;

Margono, Benjamin ;

Ichinose, Yukito ;

Nishiwaki, Yutaka ;

Ohe, Yuichiro ;

Yang, Jin-Ji ;

Chewaskulyong, Busyamas ;

Jiang, Haiyi ;

Duffield, Emma L. ;

Watkins, Claire L. ;

Armour, Alison A. ;

Fukuoka, Masahiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :947-957

[13]

Niyikiza C, 2002, MOL CANCER THER, V1, P545

[14] Global cancer statistics, 2002 [J].

Parkin, DM ;

Bray, F ;

Ferlay, J ;

Pisani, P .

CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (02) :74-108

[15]

Peterson P., 2007, Journal of Thoracic Oncology, V2, pS851

[16] Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL [J].

Reck, Martin ;

von Pawel, Joachim ;

Zatloukal, Petr ;

Ramlau, Rodryg ;

Gorbounova, Vera ;

Hirsh, Vera ;

Leighl, Natasha ;

Mezger, Joerg ;

Archer, Venice ;

Moore, Nicola ;

Manegold, Christian .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1227-1234

[17]

Ries L., 2004, SEER CANC STAT REV 1

[18] Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. [J].

Rosell, Rafael ;

Moran, Teresa ;

Queralt, Cristina ;

Porta, Rut ;

Cardenal, Felipe ;

Camps, Carlos ;

Majem, Margarita ;

Lopez-Vivanco, Guillermo ;

Isla, Dolores ;

Provencio, Mariano ;

Insa, Amelia ;

Massuti, Bartomeu ;

Luis Gonzalez-Larriba, Jose ;

Paz-Ares, Luis ;

Bover, Isabel ;

Garcia-Campelo, Rosario ;

Angel Moreno, Miguel ;

Catot, Silvia ;

Rolfo, Christian ;

Reguart, Noemi ;

Palmero, Ramon ;

Miguel Sanchez, Jose ;

Bastus, Roman ;

Mayo, Clara ;

Bertran-Alamillo, Jordi ;

Angel Molina, Miguel ;

Javier Sanchez, Jose ;

Taron, Miquel .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :958-U38

[19] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [J].

Sandler, Alan ;

Gray, Robert ;

Perry, Michael C. ;

Brahmer, Julie ;

Schiller, Joan H. ;

Dowlati, Afshin ;

Lilenbaum, Rogerio ;

Johnson, David H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) :2542-2550

[20] EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary [J].

Sant, M. ;

Aareleid, T. ;

Berrino, F. ;

Lasota, M. Bielska ;

Carli, P. M. ;

Faivre, J. ;

Grosclaude, P. ;

Hedelin, G. ;

Matsuda, T. ;

Moller, H. ;

Moller, T. ;

Verdecchia, A. ;

Capocaccia, R. ;

Gatta, G. ;

Micheli, A. ;

Santaquilani, M. ;

Roazzi, P. ;

Lisi, D. .

ANNALS OF ONCOLOGY, 2003, 14 :V61-V118

← 1 2 3 →